Mylan, Inc. (MYL) reported third quarter earnings per share of 32 cents, above both the Zacks Consensus Estimate of 27 cents and 23 cents in the prior-year period. The company reported revenues of $1.26 billion, a 24% decline from the year-ago period.

However, the year-ago period included $455 million of revenue related to the sale of the product rights of Bystolic. Excluding this, total revenues increased 5.2% over the third quarter 2008. Revenues would have increased 9%, but for the unfavorable movement of foreign currency.

From this quarter onwards, Mylan has decided to report its results in two segments — Generics and Specialty — following the acquisition of approximately 24% of the remaining interest in Matrix and the related de-listing. The former Matrix segment has been included in the Generics segment. The Generics Segment, accounting for about 88% of total revenues during the quarter Incorporatedreased marginally (3.7%) to $1.12 billion. Revenues from Specialty recorded a huge increase of 20.3% to $150.9 million.

Sales from the North American market increased 9.2% year over year to $502.5 million, primarily due to new product launches in the past 12 months along with increased volume, partially offset by unfavorable pricing as a result of additional generic competition on certain products. However, revenues from the other markets — EMEA (down 1.1%) and Asia Pacific (up 4.6%) — did not contribute much to the growth of the company.

Excluding the impact of Bystolic sale and certain purchase accounting related items, gross margins fell to 45.6% in the third quarter of 2008 compared to 46.7% in the prior year period.

Mylan is now the third-largest generic company in the world after the acquisition of Merck Generics and Matrix Labs. Currently, Mylan has 121 ANDAs pending FDA approval representing $85.7 billion in annual brand sales, according to IMS Health. Among these, 35 are potential first-to-file opportunities, representing $17.9 billion in annual brand sales.

We expect the Merck Generics acquisition to contribute significantly to the company’s long-term growth and help expand its footprint in non-US markets. Based on the strong third quarter earnings, Mylan raised its 2009 earnings guidance. The company now expects its earnings per share in the range of $1.24 – $1.28 from the earlier guidance of $1.13 – $1.20. We have a Neutral recommendation on the stock.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (CCE) Coca Cola Enterprises Beats the Consensus and Raises ExpectationsCoca Cola Enterprises (CCE) reported its second consecutive quarter of strong results, with earnings of...
2. (ALXN) Alexion Pharmaceuticals Beats, Raises OutlookYesterday, Alexion Pharmaceuticals (ALXN) came out with strong third quarter financials. The company reported earnings...
3. (MYL) Mylan Settles Dispute with PfizerRecently, Mylan (MYL) announced the settlement of its dispute with Pfizer (PFE) related to the...
4. (MYL) Mylan Drug Gets Tentative OKYesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from...
5. (MYL) Mylan, Inc. – Momentum – Zacks Rank BuyMylan, Inc.’s (MYL) share price continues to trend higher on consistent earnings and higher estimates....
6. (MYL) Mylan, Inc. – Momentum – Zacks Rank BuyMylan, Inc.’s (MYL) share price continues to head higher after the company’s solid fourth-quarter and...

Search Posts by Tag: MYL | Mylan | Drugs - Generic | Healthcare

RSS Feeds by Tag: MYL | Mylan | Drugs - Generic | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author